To do so, perhaps, NHRC, India, organises an Open House Discussion on “Measures to Curb Spurious Medicines in India”

NHRC Member, Justice (Dr.) Bidyut Ranjan Sarangi chairing the meet emphasises risks of isolated regulatory challenges translating into large-scale human distress if not addressed decisively and systematically

NHRC Member Smt. Vijaya Bharathi Sayani says, the issue requires to be urgently addressed by placing in place strengthened oversight and accountability mechanisms in the pharmaceutical ecosystem

Secretary General, Shri Bharat Lal highlights spurious drugs being different from substandard drugs but both require coordinated institutional action to combat the menace

Among various suggestion from the discussions involving multi-stakeholders stress upon the need to establish a comprehensive, centralised databank on spurious and sub-standard medicines, integrating inputs from enforcement agencies, regulators and states